Low-dose version of Prempro approved

Share this article:
The FDA approved a low-dose version of Wyeth Pharmaceuticals' hormone replacement therapy Prempro (conjugated estrogens and medroxyprogesterone). The low-dose Prempro has 28 percent less estrogen and 40 percent less progestin than full-dose Prempro, Wyeth reported. It contains 0.45 mg of conjugated estrogens and 1.5 mg of medroxyprogesterone. This version is indicated for use in the treatment of moderate to severe vasomotor symptoms associated with menopause, such as hot flashes and night sweats. It is also approved for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy, such as vaginal dryness. Wyeth said data supporting the efficacy and tolerability of low-dose Prempro is based on the Women's HOPE study, which included 2,805 postmenopausal women.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters